This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.



Drug Names(s): 212Pb-TCMC-Trastuzumab, Lead-212 radiotherapy, Pb-212 radiotherapy

Description: 212Pb is a rare isotope found in certain by-products of AREVA processes. 212Pb is used in alpha radioimmunotherapy, a targeted cancer treatment. This novel approach destroys cancer cells by transporting and delivering a short-range radioactive isotope called lead-212 (212Pb) to the cancer cell. The isotope's short-range energy then attacks the cancer cell while minimizing damage to nearby healthy cells.

Deal Structure: Roche and AREVA
In July 2012, Roche and AREVA Med announced that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.

Under this exclusive agreement, Roches Pharma Research and Early Development (pRED) organization and AREVA Med will assess the efficacy of combining Roche-engineered antibodies with AREVA Meds radionuclide, Lead-212, a compound that shows promise in treating some types of cancer. Roche retains exclusive rights to commercialise the cancer radio-immunotherapy after clinical development.

Partners: Roche Holding AG

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug